Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrONTO: Ranibizumab Variable Dosing in Neovascular AMD
NCT00373659Phase 2Completed
- Sponsor
- University of Miami
- Start
- Aug 2004
- Primary completion
- Jun 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by University of Miami. Primary endpoints: Change in Visual Acuity vs Baseline and Change in OCT Central Retinal Thickness vs Baseline. Started Aug 2004; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00373659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373659.